Autotransplant conditioning regimens for aggressive lymphoma: Are we on the right road?

Bone Marrow Transplantation

Volumn 40, Issue 6, 2007, Pages 505-513

  Fernandez, H F ^a   Escalon M P ^b   Pereira, D ^b   Lazarus, H M ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISOLONE; PREDNISONE; RITUXIMAB; THIOTEPA; TOPOTECAN; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLEEDING; BURKITT LYMPHOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; KIDNEY INJURY; LEUKEMIA; LIVER FUNCTION; LIVER INJURY; LIVER VEIN OBSTRUCTION; LUNG FIBROSIS; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; T CELL LYMPHOMA; TREATMENT OUTCOME; WASTING SYNDROME;

BONE MARROW TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 34548531511     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705744     Document Type: Review

References (65)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16 3264-3269.
3. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135.
4. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020-1026.
5. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
6. de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777-781.
7. Fernandez HF. The Use of Intravenous Busulfan and Cyclophosphamide as a Conditioning Regimen for Non-Hodgkin's Lymphoma. ASBMT/CIBMTR Tandem Meetings. Honolulu, HI, 2006.
8. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96-102.
9. Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
10. Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR et al. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 257-262.
11. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48-55.
12. Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/ refractory lymphoma: An effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 2005; 11: 13-22.
13. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-Cell lymphoma. N Engl J Med 1997; 336: 1290-1298.
14. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562-3568.
15. Leonard BM, Hetu F, Busque L, Gyger M, Belanger R, Perreault C et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: Less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91: 331-339.
16. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
17. Galimberti S, Marasca R, Caracciolo F, Fazzi R, Papineschi F, Benedetti E et al. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 581-587.
18. Blystad A, Kvalheim G, Torlakovic E, Holte H, Jacobsen E, Beiske K et al. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 865-872.
19. van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: In vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132: 42-55.
20. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454-2464.
21. Cilley J, Winter JN. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006; 91: 114-120.
22. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561-4566.
23. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1569-1573.
24. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-632.
25. Khouri IF, Saliba RM, Hosing C, Okoroji G-J, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247.
26. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-1224.
27. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336-340.
28. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
29. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461-467.
30. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896-2902.
31. Fung HC, Forman SJ, Nademanee A, Molina D, Yamauchi R, Speilberger N et al. A new preparative regimen for older patients with aggressive CD20-positive B-cell lymphoma utilizing standard-dose yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): Targeted intensification without increased transplant-related toxicity. ASH Annu Meeting Abstr 2003; 102: 248a. Abstract #870.
32. Winter JN, Inwards D, Spies S, Wiseman G, Patton D, Erwin W et al. 90Y Ibritumomab Tiuxetan (Zevalin(R); 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. ASH Annu Meeting Abstr 2006; 108: 330.
33. Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769-775.
34. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
35. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998; 16: 2796-2802.
36. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
37. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
38. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
39. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
40. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiCCOM: A 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133-138.
41. Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14: 2465-2472.
42. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19: 2927-2936.
43. Levine JE, Harris RE, Loberiza Jr FR, Armitage JO, Vose JM, Van Besien K et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476-2482.
44. Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711-716.
45. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372-1377.
46. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience. Ann Oncol 2003; 14: 1768-1775.
47. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001; 12: 923-927.
48. Muller-Beissenhirtz H, Kasper C, Nuckel H, Duhrsen U. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol 2005; 84: 796-801.
49. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster SJ, Dyer MJS et al. Rituximab-relapsing patients with non-hodgkins lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20): Phase I/II results. ASH Annu Meeting Abstr 2006; 108 2719.
50. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868-2878.
51. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
52. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leak Lymphoma 2006; 47: 998-1005.
53. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouhde Parseval L, Jensen-Pergakes K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B-cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
54. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59-70.
55. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 2000; 95: 1588-1593.
56. Douglas S, Smith C, McFarland R, Badel K, Calandra G. AMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM): Mobilization, engraftment, and pharmacokinetics (PK). ASH Annual Meeting Abstracts 2006; 108: 3383.
57. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577.
58. Lien S, Larsson AK, Mannervik B. The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1, 3-bis(2-chloroethyl)-1-nitrosourea. Biochem Pharmacol 2002; 63 191-197.
59. Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23: 6117-6125.
60. Filicko J, Lazarus HM, Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: New approaches to prophylaxis and treatment. Bone Marrow Transplant 2003; 31 1-10.
61. Anaissie E, Schuster M, Hurd D. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT). Biol Blood Marrow Transplant 2006; 12: 21.
62. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186-5193.
63. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-4669.
64. Holmberg LA, Maloney D, Bensinger W. Immunotherapy with rituximab/ interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006; 7 135-139.
65. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.